<?xml version="1.0" encoding="UTF-8"?>
<eudamedExport entity="devices">
  <row>
    <udiDi>04028694001390</udiDi>
    <basicUdiDi>4028694VISMED3F</basicUdiDi>
    <tradeName>04028694001390</tradeName>
    <deviceName></deviceName>
    <manufacturerName>TRB Chemedica AG</manufacturerName>
    <manufacturerSrn>DE-MF-000006919</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIb</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode>Q02030301</emdnCode>
    <emdnDescription>OPHTHALMOLOGY, HYALURONIC ACID AND DERIVATIVES</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>04028694001390</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-07-09T11:57:55.393Z</lastUpdated>
  </row>
  <row>
    <udiDi>04028694001406</udiDi>
    <basicUdiDi>4028694VISMED3F</basicUdiDi>
    <tradeName>HYLOVIS®</tradeName>
    <deviceName></deviceName>
    <manufacturerName>TRB Chemedica AG</manufacturerName>
    <manufacturerSrn>DE-MF-000006919</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIb</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode>Q02030301</emdnCode>
    <emdnDescription>OPHTHALMOLOGY, HYALURONIC ACID AND DERIVATIVES</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>04028694001406</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-07-09T11:57:55.369Z</lastUpdated>
  </row>
  <row>
    <udiDi>04028694001413</udiDi>
    <basicUdiDi>4028694VISGELM7S</basicUdiDi>
    <tradeName>04028694001413</tradeName>
    <deviceName></deviceName>
    <manufacturerName>TRB Chemedica AG</manufacturerName>
    <manufacturerSrn>DE-MF-000006919</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIb</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode>Q02030301</emdnCode>
    <emdnDescription>OPHTHALMOLOGY, HYALURONIC ACID AND DERIVATIVES</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>04028694001413</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-07-09T11:57:55.352Z</lastUpdated>
  </row>
  <row>
    <udiDi>04028694001420</udiDi>
    <basicUdiDi>4028694VISGELM7S</basicUdiDi>
    <tradeName>04028694001420</tradeName>
    <deviceName></deviceName>
    <manufacturerName>TRB Chemedica AG</manufacturerName>
    <manufacturerSrn>DE-MF-000006919</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIb</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode>Q02030301</emdnCode>
    <emdnDescription>OPHTHALMOLOGY, HYALURONIC ACID AND DERIVATIVES</emdnDescription>
    <deviceStatus>AB pazarı için değil</deviceStatus>
    <reference>04028694001420</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-07-09T11:57:55.337Z</lastUpdated>
  </row>
  <row>
    <udiDi>04028694001437</udiDi>
    <basicUdiDi>4028694VISGELM7S</basicUdiDi>
    <tradeName>HYLOVIS® GEL MULTI</tradeName>
    <deviceName></deviceName>
    <manufacturerName>TRB Chemedica AG</manufacturerName>
    <manufacturerSrn>DE-MF-000006919</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIb</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode>Q02030301</emdnCode>
    <emdnDescription>OPHTHALMOLOGY, HYALURONIC ACID AND DERIVATIVES</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>04028694001437</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-07-09T11:57:55.316Z</lastUpdated>
  </row>
  <row>
    <udiDi>04028694001468</udiDi>
    <basicUdiDi>4028694VISMULTIMH</basicUdiDi>
    <tradeName>04028694001468</tradeName>
    <deviceName></deviceName>
    <manufacturerName>TRB Chemedica AG</manufacturerName>
    <manufacturerSrn>DE-MF-000006919</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIb</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode>Q02030301</emdnCode>
    <emdnDescription>OPHTHALMOLOGY, HYALURONIC ACID AND DERIVATIVES</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>04028694001468</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-07-09T11:57:55.302Z</lastUpdated>
  </row>
  <row>
    <udiDi>04028694001475</udiDi>
    <basicUdiDi>4028694VISMULTIMH</basicUdiDi>
    <tradeName>04028694001475</tradeName>
    <deviceName></deviceName>
    <manufacturerName>TRB Chemedica AG</manufacturerName>
    <manufacturerSrn>DE-MF-000006919</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIb</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode>Q02030301</emdnCode>
    <emdnDescription>OPHTHALMOLOGY, HYALURONIC ACID AND DERIVATIVES</emdnDescription>
    <deviceStatus>AB pazarı için değil</deviceStatus>
    <reference>04028694001475</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-07-09T11:57:55.283Z</lastUpdated>
  </row>
  <row>
    <udiDi>04028694001499</udiDi>
    <basicUdiDi>4028694VISMULTIMH</basicUdiDi>
    <tradeName>HYLOVIS® Multi</tradeName>
    <deviceName></deviceName>
    <manufacturerName>TRB Chemedica AG</manufacturerName>
    <manufacturerSrn>DE-MF-000006919</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIb</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode>Q02030301</emdnCode>
    <emdnDescription>OPHTHALMOLOGY, HYALURONIC ACID AND DERIVATIVES</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>04028694001499</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-07-09T11:57:55.260Z</lastUpdated>
  </row>
  <row>
    <udiDi>08680548905641</udiDi>
    <basicUdiDi>B-08680548905641</basicUdiDi>
    <tradeName>HYOTEK</tradeName>
    <deviceName>Sterile viscoelastic solution –  Sodium Hyaluronate - Hyotek 1% 0.55ml</deviceName>
    <manufacturerName>TEKNOMEK MEDİKAL MALZEMELERİ SAN. ve TİC. LTD. ŞTİ.</manufacturerName>
    <manufacturerSrn>TR-MF-000018462</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIb</riskClass>
    <legislation>MDD</legislation>
    <emdnCode>Q02030301</emdnCode>
    <emdnDescription>OPHTHALMOLOGY, HYALURONIC ACID AND DERIVATIVES</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>CT1V55M</reference>
    <placedOnMarketCountry>Türkiye</placedOnMarketCountry>
    <lastUpdated>2026-07-08T02:47:47.026Z</lastUpdated>
  </row>
  <row>
    <udiDi>08437015992778</udiDi>
    <basicUdiDi>B-08437015992778</basicUdiDi>
    <tradeName>Supralon 2%</tradeName>
    <deviceName>Supralon</deviceName>
    <manufacturerName>i+Med S.Coop.</manufacturerName>
    <manufacturerSrn>ES-MF-000008633</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIb</riskClass>
    <legislation>MDD</legislation>
    <emdnCode>Q02030301</emdnCode>
    <emdnDescription>OPHTHALMOLOGY, HYALURONIC ACID AND DERIVATIVES</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>-</reference>
    <placedOnMarketCountry>Spain</placedOnMarketCountry>
    <lastUpdated>2026-07-07T21:53:10.525Z</lastUpdated>
  </row>
  <row>
    <udiDi>08437015992761</udiDi>
    <basicUdiDi>B-08437015992761</basicUdiDi>
    <tradeName>Supralon 1,4%</tradeName>
    <deviceName>Supralon</deviceName>
    <manufacturerName>i+Med S.Coop.</manufacturerName>
    <manufacturerSrn>ES-MF-000008633</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIb</riskClass>
    <legislation>MDD</legislation>
    <emdnCode>Q02030301</emdnCode>
    <emdnDescription>OPHTHALMOLOGY, HYALURONIC ACID AND DERIVATIVES</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>-</reference>
    <placedOnMarketCountry>Spain</placedOnMarketCountry>
    <lastUpdated>2026-07-07T21:53:09.551Z</lastUpdated>
  </row>
  <row>
    <udiDi>08437015992327</udiDi>
    <basicUdiDi>B-08437015992327</basicUdiDi>
    <tradeName>OpHLINE 3.0%</tradeName>
    <deviceName>OpHLINE</deviceName>
    <manufacturerName>i+Med S.Coop.</manufacturerName>
    <manufacturerSrn>ES-MF-000008633</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIb</riskClass>
    <legislation>MDD</legislation>
    <emdnCode>Q02030301</emdnCode>
    <emdnDescription>OPHTHALMOLOGY, HYALURONIC ACID AND DERIVATIVES</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>-</reference>
    <placedOnMarketCountry>Spain</placedOnMarketCountry>
    <lastUpdated>2026-07-07T21:53:08.759Z</lastUpdated>
  </row>
  <row>
    <udiDi>08437015992310</udiDi>
    <basicUdiDi>B-08437015992310</basicUdiDi>
    <tradeName>OpHLINE 2.0%</tradeName>
    <deviceName>OpHLINE</deviceName>
    <manufacturerName>i+Med S.Coop.</manufacturerName>
    <manufacturerSrn>ES-MF-000008633</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIb</riskClass>
    <legislation>MDD</legislation>
    <emdnCode>Q02030301</emdnCode>
    <emdnDescription>OPHTHALMOLOGY, HYALURONIC ACID AND DERIVATIVES</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>-</reference>
    <placedOnMarketCountry>Spain</placedOnMarketCountry>
    <lastUpdated>2026-07-07T21:53:04.756Z</lastUpdated>
  </row>
  <row>
    <udiDi>08437015992303</udiDi>
    <basicUdiDi>B-08437015992303</basicUdiDi>
    <tradeName>OpHLINE 1.4%</tradeName>
    <deviceName>OpHLINE</deviceName>
    <manufacturerName>i+Med S.Coop.</manufacturerName>
    <manufacturerSrn>ES-MF-000008633</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIb</riskClass>
    <legislation>MDD</legislation>
    <emdnCode>Q02030301</emdnCode>
    <emdnDescription>OPHTHALMOLOGY, HYALURONIC ACID AND DERIVATIVES</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>-</reference>
    <placedOnMarketCountry>Spain</placedOnMarketCountry>
    <lastUpdated>2026-07-07T21:53:03.956Z</lastUpdated>
  </row>
  <row>
    <udiDi>08437015992051</udiDi>
    <basicUdiDi>B-08437015992051</basicUdiDi>
    <tradeName>OpHLINE 3.0%</tradeName>
    <deviceName>OpHLINE</deviceName>
    <manufacturerName>i+Med S.Coop.</manufacturerName>
    <manufacturerSrn>ES-MF-000008633</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIb</riskClass>
    <legislation>MDD</legislation>
    <emdnCode>Q02030301</emdnCode>
    <emdnDescription>OPHTHALMOLOGY, HYALURONIC ACID AND DERIVATIVES</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>PV00006</reference>
    <placedOnMarketCountry>Spain</placedOnMarketCountry>
    <lastUpdated>2026-07-07T21:52:56.755Z</lastUpdated>
  </row>
  <row>
    <udiDi>08437015992044</udiDi>
    <basicUdiDi>B-08437015992044</basicUdiDi>
    <tradeName>OpHLINE 2.0%</tradeName>
    <deviceName>OpHLINE</deviceName>
    <manufacturerName>i+Med S.Coop.</manufacturerName>
    <manufacturerSrn>ES-MF-000008633</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIb</riskClass>
    <legislation>MDD</legislation>
    <emdnCode>Q02030301</emdnCode>
    <emdnDescription>OPHTHALMOLOGY, HYALURONIC ACID AND DERIVATIVES</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>PV00004</reference>
    <placedOnMarketCountry>Spain</placedOnMarketCountry>
    <lastUpdated>2026-07-07T21:52:40.695Z</lastUpdated>
  </row>
  <row>
    <udiDi>08437015992037</udiDi>
    <basicUdiDi>B-08437015992037</basicUdiDi>
    <tradeName>OpHLINE 1.4%</tradeName>
    <deviceName>OpHLINE</deviceName>
    <manufacturerName>i+Med S.Coop.</manufacturerName>
    <manufacturerSrn>ES-MF-000008633</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIb</riskClass>
    <legislation>MDD</legislation>
    <emdnCode>Q02030301</emdnCode>
    <emdnDescription>OPHTHALMOLOGY, HYALURONIC ACID AND DERIVATIVES</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>PV00002</reference>
    <placedOnMarketCountry>Spain</placedOnMarketCountry>
    <lastUpdated>2026-07-07T21:52:38.295Z</lastUpdated>
  </row>
  <row>
    <udiDi>07290008069212</udiDi>
    <basicUdiDi>B-07290008069212</basicUdiDi>
    <tradeName>BIOLON</tradeName>
    <deviceName></deviceName>
    <manufacturerName>Bio-Technology General (Israel) Ltd.</manufacturerName>
    <manufacturerSrn>IL-MF-000003764</manufacturerSrn>
    <authorisedRepresentativeName>Ferring Pharmaceuticals A/S</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>DK-AR-000001206</authorisedRepresentativeSrn>
    <riskClass>Sınıf IIb</riskClass>
    <legislation>MDD</legislation>
    <emdnCode>Q02030301</emdnCode>
    <emdnDescription>OPHTHALMOLOGY, HYALURONIC ACID AND DERIVATIVES</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>6301182002</reference>
    <placedOnMarketCountry>Spain</placedOnMarketCountry>
    <lastUpdated>2026-07-06T23:59:29.061Z</lastUpdated>
  </row>
  <row>
    <udiDi>07290008069182</udiDi>
    <basicUdiDi>B-07290008069182</basicUdiDi>
    <tradeName>BIOLON prime</tradeName>
    <deviceName></deviceName>
    <manufacturerName>Bio-Technology General (Israel) Ltd.</manufacturerName>
    <manufacturerSrn>IL-MF-000003764</manufacturerSrn>
    <authorisedRepresentativeName>Ferring Pharmaceuticals A/S</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>DK-AR-000001206</authorisedRepresentativeSrn>
    <riskClass>Sınıf IIb</riskClass>
    <legislation>MDD</legislation>
    <emdnCode>Q02030301</emdnCode>
    <emdnDescription>OPHTHALMOLOGY, HYALURONIC ACID AND DERIVATIVES</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>6301182003</reference>
    <placedOnMarketCountry>Spain</placedOnMarketCountry>
    <lastUpdated>2026-07-06T23:59:27.449Z</lastUpdated>
  </row>
  <row>
    <udiDi>04260595531846</udiDi>
    <basicUdiDi>B-04260595531846</basicUdiDi>
    <tradeName>opticol® OSD</tradeName>
    <deviceName>Moisturizing Eye Drops</deviceName>
    <manufacturerName>Penta Arzneimittel GmbH</manufacturerName>
    <manufacturerSrn>DE-MF-000006565</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIb</riskClass>
    <legislation>MDD</legislation>
    <emdnCode>Q02030301</emdnCode>
    <emdnDescription>OPHTHALMOLOGY, HYALURONIC ACID AND DERIVATIVES</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>41095500L</reference>
    <placedOnMarketCountry>Portugal</placedOnMarketCountry>
    <lastUpdated>2026-07-06T04:53:23.971Z</lastUpdated>
  </row>
</eudamedExport>